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Abstract We investigated the expression and function of P2
receptors and ecto-nucleotidases on human monocyte derived
dendritic cells (DC). In addition we analyzed the effect of
extracellular ATP on the maturation of DC. By RT-PCR, DC
were found to express mRNA for several P2X (P2X1, P2X4,
P2X5, P2X7) and P2Y (P2Y1, P2Y2, P2Y4, P2Y5, P2Y6,
P2Y10, P2Y11) receptors. As shown by FURA-2 measurement,
triggering of P2 receptors resulted in an increase in free
intracellular Ca2+. In combination with Tumor necrosis factor-
K, ATP increased the expression of the DC surface markers
CD80, CD83 and CD86 indicating a maturation promoting
effect. DC expressed the ecto-apyrase CD39 and the ecto-5P-
nucleotidase CD73 as demonstrated by RT-PCR. Extracellular
ATP was rapidly hydrolyzed by these ecto-enzymes as shown by
separation of 3H-labeled ATP metabolites using a thin layer
technique. These data suggest that ATP acts as a costimulatory
factor on DC maturation.
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1. Introduction
Dendritic cells (DC) are the most potent antigen presenting
cells of the immune system. In their immature stage they re-
side in peripheral tissues. Upon encountering antigen, like
pathogens, they migrate to lymphoid organs where they trig-
ger a speci¢c T cell response [1]. Recently, DC have also come
to represent a very interesting cell type for gene therapy and
vaccination strategies against tumors and viral infections [2].
In vitro, immature DC can be generated from peripheral
blood monocytes by culturing them in the presence of gran-
ulocyte-macrophage colony stimulating factor (GM-CSF) and
interleukin (IL)-4 [3,4]. These cells show high endocytic, but
low T cell stimulatory capacity. Upon addition of monocyte
conditioned medium [5] or a cocktail (IL-1L, IL-6, tumor
necrosis factor K (TNF-K) and prostaglandin E2 (PGE2))
that mimics it, these DC develop into fully mature immuno-
stimulatory cells [6].
Extracellular ATP a¡ects the function of many tissues and
cell types and has also been shown to exert immunomodula-
tory functions. It regulates, for example, the function of B and
T cells [7,8] and induces cell death in macrophages [9]. ATP
can be released by regulated exocytosis of vesicles and gran-
ules or by traumatic lysis of intact cells [10]. ATP mediates its
e¡ects by binding to P2 nucleotide receptors [11^13]. These
belong to two main classes: G protein coupled metabotropic
P2Y receptors and ionotropic ATP gated channels termed
P2X receptors [11]. Both classes comprise a number of sub-
types [14]. Signaling through P2Y receptors results in mobil-
ization of inositol 1,4,5-triphosphate sensitive Ca2 stores,
activation of plasma membrane in£ux pathways and stimula-
tion of diglyceride dependent protein kinase C enzymes [15].
Signaling through P2 receptors is terminated by hydrolysis of
ATP by ecto-ATPases degrading ATP to ADP, ecto-apyrases
catabolizing ATP and ADP to AMP and ecto-5P-nucleotidases
catabolizing AMP into adenosine [16,17]. CD73, originally
identi¢ed on B cells, has been found to be the major ecto-
5P-nucleotidase [18], CD39, another B cell surface marker, is
an ecto-apyrase [19].
Epidermal Langerhans cells have previously been shown to
express membrane ATPase which appears to protect them
against the cytotoxic e¡ects of extracellular ATP [20^22].
Very little, however, is known about the expression and func-
tion of P2 receptors and ATPases on DC. Only recently it has
been shown that DC express functional P2Y receptors [23]. In
the present study we show the expression and functional char-
acterization of several P2X (P2X1, P2X4, P2X5, P2X7) and
P2Y (P2Y1, P2Y2, P2Y4, P2Y5, P2Y6, P2Y10, P2Y11) re-
ceptors as well as ATPases and 5P-ecto-nucleotidases on hu-
man DC during di¡erent maturation stages.
2. Materials and methods
2.1. Culture medium
RPMI 1640 (Bio Whittaker, Verviers, Belgium) was supplemented
with 2 mM L-glutamine (Life Technologies, Karlsruhe, Germany), 100
IU/ml penicillin (Sigma, Deisenhofen, Germany), 100 Wg/ml strepto-
mycin (Sigma), 10 mM HEPES pH 7.0 (Sigma) and 10% heat inacti-
vated fetal calf serum (PAA, Co«lbe, Germany) (also termed complete
medium).
2.2. Cytokines and ATP
Recombinant human cytokines were used in the following ¢nal
concentrations: GM-CSF (Leukomax, Novartis, Basel, Switzerland)
800 U/ml, IL-4 (Novartis, Vienna, Austria) 1000 U/ml, IL-1L (Sigma)
10 ng/ml, IL-6 (Sandoz, Basel) 1000 U/ml, PGE2 (Sigma) 1 Wg/ml,
TNF-K (Bender, Vienna, Austria) 25 ng/ml. ATP (Sigma) was used at
a concentration of 100 WM.
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2.3. Antibodies
For immunostaining, mouse IgG CD14 (Dianova, Hamburg, Ger-
many), CD80 (Immunotech, Marseille, France), CD83 (Immunotech),
CD86 (Dianova) and mouse IgG subclass speci¢c isotypes were used.
Secondary antibody was biotinylated anti-mouse IgG (Amersham
Pharmacia Biotech, Freiburg, Germany), staining was performed
with streptavidin conjugated FITC (Amersham Pharmacia Biotech).
Alternatively FITC or PE conjugated CD14 and CD83 and the iso-
type speci¢c FITC and PE conjugated mouse IgG were used.
2.4. Oligonucleotides
For PCR ampli¢cation, the following gene speci¢c primers were
used: P2X2 sense 5P-CTG TGA AGA CGT GTG AGA TCT TTG
G-3P, P2X2 antisense 5P-TTG AAG AGG TGA CGG TAG TTG
GTC C-3P ; P2X4 sense 5P-GAG ATT CCA GAT GCG ACC-3P ;
P2X4 antisense 5P-GAC TTG AGG TAA GTA GTG G-3P ; P2X5
sense 5P-TCG ACT ACA AGA CCG AGA AG-3P ; P2X5 antisense
5P-CTT GAC GTC CAT CAC ATT G-3P [24]; P2X7 sense 5P-AAC
ATC ACT TGT ACC TTC C-3P ; P2X7 antisense 5P-TGT GAA GTC
CAT CGC AGG-3P ; P2Y1 sense 5P-CTA CAT CTT GGT ATT CAT
CAT CGG-3P, P2Y1 antisense 5P-GAG ACT TGC TAG ACC TCT
TGT CAC C-3P [25]; P2Y2 sense 5P-CTC TAC TTT GTC ACC ACC
AGC GCG-3P, P2Y2 antisense 5P-TTC TGC TCC TAC AGC CGA
ATG TCC-3P [25]; P2Y4 sense 5P-CCA CCT GGC ATT GTC AGA
CAC C-3P ; P2Y4 antisense 5P-GAG TGA CCA GGC AGG GCA
CGC-3P [26] ; P2Y5 sense 5P-TGG TTA ACT GTG ATC GGA GG-
3P ; P2Y5 antisense 5P-AGT CAC TTC TCC TGA CAG ACC-3P ;
P2Y6 sense 5P-CGC TTC CTC TTC TAT GCC AAC C-3P ; P2Y6
antisense 5P-CCA TCC TGG CGG CAC AGG CGG C-3P [26];
P2Y10 sense 5P-CAT CAG TCT TCA AAG GTG C-3P ; P2Y10 anti-
sense 5P-GGA CAA CTG CTA ATG ATG G-3P ; P2Y11 sense 5P-
CAG CGT CAT CTT CAT CAC C-3P ; P2Y11 antisense 5P-GCT
ATA CGC TCT GTA GGC-3P ; CD73 sense 5P-CAC CAA GGT
TCA GCA GAT CCG C-3P, CD73 antisense 5P-GTT CAT CAA
TGG GCG ACC GG [25]; CD39 sense 5P-GAC CCA GAA CAA
AGC ATT GCC-3P, CD39 antisense 5P-TGT AGT CCT TGC CAG
AGA GGC G-3P [25]; GAPDH sense 5P-CAC CAC CAT GGA GAA
GGC TGG-3P, GAPDH antisense 5P-GAA GTC AGA GGA GAC
CAC CAG-3P. Oligonucleotides were obtained from MWG Biotech
(Ebersberg, Germany) or Amersham Pharmacia Biotech.
2.5. Cell preparation
Peripheral blood mononuclear cells (PBMC) were isolated from
bu¡y coats using Lymphoprep (Nycomed Pharma, Oslo, Norway).
Cells were plated onto IgG (Sigma) coated bacteriological 10 cm petri
dishes (Falcon, Germany) at a concentration of 50U106/ml (Kruse et
al., manuscript in preparation). After 45 min, non-adherent cells were
rinsed o¡ the dishes. Eight hours later medium was replaced by fresh
medium supplemented with 800 U/ml GM-CSF and 1000 U/ml IL-4.
On day 3 cells were fed with fresh medium (+5 ml) containing
400 U/ml GM-CSF and 500 U/ml IL-4. On day 4 or 5, non-adherent
cells were rinsed o¡ the dishes, washed once and transferred to tissue
culture dishes at a density of 250 000 cells/ml. The next day, cells were
stimulated with di¡erent combinations of cytokines and ATP. Macro-
phages were generated by plating PBMC onto IgG coated bacterio-
logical dishes and culturing the adherent fraction in complete medium
supplemented with 800 U GM-CSF/ml. After 7 days adherent cells
were harvested.
2.6. Flow cytometry analysis
Staining and washing was performed in PBS (136 mM NaCl, 8 mM
Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl pH 7.4) plus 1% FCS.
Cells were incubated for 30 min on ice with each antibody in the
appropriate dilution. After washing once, cells were incubated for
20 min with the secondary antibody and for 15 min with streptavi-
din-FITC. After washing once with PBS cells were analyzed by £ow
cytometry (FACScan, Becton Dickinson, Mountain View, CA, USA).
2.7. RT-PCR
Total RNA was isolated using TriFast reagent (Peqlab, Erlangen,
Germany) according to the manufacturer’s instructions and digested
with RNase free DNase I (Life Technologies). DNase treated RNA (2
Wg) was reverse transcribed into cDNA using SuperScript II (Life
Technologies). cDNA reactions were performed for 1 h at 42‡C and
stopped by boiling for 5 min. 2 Wl of cDNA was used as a template
for PCR with primers speci¢c for P2X1, P2X4, P2X5, P2X7, P2Y1,
P2Y2, P2Y4, P2Y5, P2Y6, P2Y10, P2Y11, CD73 and CD39. As a
control for cDNA synthesis, GAPDH-PCR was performed. PCR re-
actions included 0.5 WM of each primer, 200 WM of dNTP, 1 U Taq
polymerase (Amersham Pharmacia Biotech) in the supplied reaction
bu¡er. The PCR cycling conditions were as follows: for P2X1 recep-
tor 45 s at 94‡C, 45 s at 64‡C, 1 min 30 s at 72‡C (ampli¢cation
product 463 bp); for P2X4, P2X7 and P2Y5 receptors 45 s at 94‡C,
45 s at 54‡C, 1 min at 72‡C (ampli¢cation products: P2X4 296 bp,
P2X7 675 bp, P2Y5 520 bp); for P2X5 receptor 45 s at 94‡C, 45 s at
57‡C, 45 s at 72‡C (ampli¢cation product 596 bp); for P2Y1 receptor
45 s at 94‡C, 45 s at 64‡C, 1 min 30 s at 72‡C (ampli¢cation product
772 bp); for P2Y2 receptor 45 s at 94‡, 45 s at 67‡C, 1 min 30 s at
72‡C (ampli¢cation product 637 bp); for P2Y4 and P2Y6 receptor 45
s at 94‡C, 45 s at 56.5‡C, 1 min at 72‡C (ampli¢cation products:
P2Y4 425 bp, P2Y6 365 bp); for P2Y10 receptor 45 s at 94‡C, 45 s
at 52‡C, 1 min at 72‡C (ampli¢cation product 456 bp); for P2Y11
receptor 45 s at 94‡C, 45 s at 57‡C, 1 min at 72‡C (ampli¢cation
product 273 bp); for CD39 45 s at 94‡C, 45 s at 62‡C, 1 min 30 s
at 72‡C (ampli¢cation product 632 bp); for CD73 45 s at 94‡C, 45 s at
64‡C, 1 min 30 s at 72‡C (ampli¢cation product 1006 bp); for
GAPDH 45 s at 94‡C, 45 s at 60‡C, 1 min 30 s at 72‡C (ampli¢cation
product 553 bp). All PCRs were carried out for 35 cycles and included
an initial 3 min denaturation step at 94‡C and a ¢nal 10 min extension
at 72‡C.
2.8. Intracellular free [Ca2+] measurements
Free intracellular calcium was measured using the £uorescence in-
dicator FURA-2AM as described [27]. Brie£y, 5U106 DC were har-
vested on day 7, centrifuged and resuspended in 1 ml RPMI supple-
mented with 10% FCS. While shaking gently, 4 Wl FURA-2AM
(stock: 1 mM in DMSO) at a ¢nal concentration of 4 WM was added.
Cells were incubated 15 min at 37‡C, then diluted 1/5, centrifuged
(300Ug), washed once and resuspended in 6 ml medium for Ca2
measurement (RPMI, 140 mM NaCl, 5 mM KCl, 1 mM MgSO4,
1 mM CaCl2, 20 mM HEPES, 1 mM NaH2PO4 and 5.5 mM glucose,
pH 7.4). Fluorescence in a 2 ml suspension was determined in a LS-3B
£uorometer (Perkin Elmer, Uº berlingen, Germany) equipped with a
chart recorder. Excitation wavelength was 340 nm, emission wave-
length was 510 nm. All measurements were carried out at room tem-
perature. Maximal £uorescence was determined by addition of 0.1%
Triton X-100, minimal £uorescence by addition of 20 Wl EGTA/Tris
(4 mM EGTA and 40 mM Tris, pH 7.4).
2.9. Assay of nucleotide metabolism by cellular ecto-enzymes
For measurement of membrane bound nucleotide metabolizing en-
zyme activities, DC were harvested and washed twice in HBSS
(Hanks’ balanced salt solution). 2U105 cells in 50 Wl HBSS were
mixed with 50 Wl HBSS containing 5 WM [3H]ATP or 5 WM [3H]AMP.
3 Wl of cell suspension supernatant was spotted directly and at indi-
cated timepoints onto PEI-cellulose thin layer sheets, a procedure that
was found to interrupt all enzymatic activities in less than 30 s [28]. A
mixture of marker nucleotides was added to each spot on the sheet.
Separation was achieved with water and after drying with 0.85 M LiCl
at room temperature. After drying, separated nucleotides were
marked under UV light and excised. Radioactivity was determined
in a scintillation mixture (toluene, 0.5% 2,5-diphenyloxazol, 0.03%
dimethyl-[1,4-bis(4-methyl-5-phenoxyloxazol-2-yl)benzene]) in a L-
counter.
3. Results
3.1. Expression of P2X and P2Y receptors in DC
To analyze the expression of P2X and P2Y receptors in DC
generated from bu¡y coats, cells were either left untreated or
stimulated with ATP alone or with a maturation cocktail (IL-
1L, IL-6, TNF-K and PGE2) or with a combination of cock-
tail and ATP. To investigate receptor expression on immature
DC, cells were harvested on day 4 without stimulation and
controlled using FACS analysis. After stimulation with the
maturation cocktail, more than 85% of cells expressed CD83
whereas among untreated and immature cells less than 20%
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were positive for this marker. Total RNA was isolated and
RT-PCR was performed with primers speci¢c for P2X1,
P2X4, P2X5, P2X7, P2Y1, P2Y2, P2Y4, P2Y5, P2Y6,
P2Y10 and P2Y11. Apart from DC, the following ¢ve cell
types were also analyzed for their receptor expression: LB23
melanoma cells, Jurkat T cells, HL-60 promyelocytes, macro-
phages and DO11, a mouse T cell hybridoma cell line which
served as a control for the speci¢city of the primers. Whereas
myeloid cells have been reported to express either P2Y1 or
P2Y2 receptors depending on their developmental stage [25],
DC express all P2Y receptors analyzed as well as P2X recep-
tors independent of stimulation (Table 1) and degree of ma-
turity.
3.2. ATP enhances the maturation inducing e¡ect of TNF-K
During maturation, DC upregulate the expression of the
surface markers CD80, CD83 and CD86. To investigate
whether ATP has an e¡ect on this upregulation, DC were
stimulated on day 5 or 6 either with ATP or with TNF-K
alone or with a combination of TNF-K and ATP or left un-
treated. Twenty-four hours later FACS analysis was per-
formed. Whereas ATP alone only modestly upregulated the
expression of CD80, CD83 and CD86, the combination of
ATP and TNF-K was clearly superior to TNF alone in induc-
ing the expression of these maturation markers (Fig. 1).
3.3. Dendritic cells respond to extracellular ATP with
intracellular Ca2+ increase
Most P2Y receptors couple to G proteins thus activating
phospholipase C. This leads to the cleavage of phosphatidyl-
inositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-triphos-
phate (IP3) which releases Ca2 from intracellular stores and
diacylglycerol thus activating protein kinase C (PKC). In-
crease of intracellular Ca2 was used as a readout for P2Y-
receptor signaling in DC. Cells were loaded with the £uores-
cence indicator FURA-2 as described above. The addition of
ATP or other nucleotides at indicated concentrations to im-
mature DC led to an increase of £uorescence intensity re£ect-
ing release of Ca2 from intracellular stores (Fig. 2, upper
panel). DC responded to 10 WM ATP with a rapid short
increase of £uorescence intensity whereas a higher concentra-
tion of ATP (100 WM) led to a concentration dependent pro-
longation of the £uorescence peak (Fig. 2). The ¢rst phase is
mainly due to Ca2 release from intracellular stores, the sec-
ond re£ects Ca2 in£ux across the plasma membrane. As
previously shown for macrophages [9], these data suggest
the presence of two receptor subtypes on DC: P2Y receptors
mediating IP3 formation and mobilization of intracellular
Ca2 resulting in a short peak of increased £uorescence inten-
sity, and at higher concentrations P2X receptor signaling lead-
ing to a pore forming ion channel for extracellular Ca2. This
hypothesis is supported by the ¢nding that complexing extrac-
ellular Ca2 by equimolar concentrations of EGTA abolished
the second phase of the response (Fig. 2, upper panel).
Table 1
Expression analysis of P2X and P2Y receptors
P2X1 P2Y1 P2Y2 P2X4 P2X5 P2X7 P2Y4 P2Y5 P2Y6 P2Y10 P2Y11
LB23 + 3 + + + 3 + 3 + 3 +
Jurkat + + 3 + + + + + 3 + +
Macrophages + + + + + + + + + + +
DO11 3 3 3 3 3 3 3 + 3 3 3
HL-60 + 3 + + 3 + + + + 3 +
DC d4 + + + + + + + + + + +
DC d7 + + + + + + + + + + +
DC+ATP + + + + + + + + + + +
DC+TIIP + + + + + + + + + + +
DC+TIIP+ATP + + + + + + + + + + +
RNA was extracted from the indicated cells and cell lines. DC were harvested either on day 4 (DC d4) or on day 7 (DC d7) and stimulated
with ATP (+ATP), TNF-K+IL-1L+IL-6+PGE2 (+TIIP), or TNF-K+IL-1L+IL-6+PGE2+ATP (+TIIP+ATP). RT-PCR was performed with
primers speci¢c for the indicated P2X and P2Y receptors.
Fig. 1. Phenotypic analysis of di¡erently stimulated DC. DC ob-
tained from bu¡y coats were cultured as described. One day after
transfer cells were stimulated as indicated or left untreated. On the
following day cells were stained with antibodies against CD80,
CD83 and CD86 and FACS analysis was performed. The mean £u-
orescence intensity of one representative experiment out of ¢ve is
shown.
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Next we investigated whether there was a di¡erence in P2X
and P2Y receptor signaling between immature and mature
DC. As indicated in Fig. 2 (lower panel) the second phase
of response to ATP triggering at a high concentration (100
WM) was signi¢cantly longer in mature DC when compared
with immature DC. Complexing extracellular Ca2 by EGTA
again abrogated the second phase of response indicating that
it was due to the in£ux of extracellular Ca2 (Fig. 2, bottom
panel). The rapid increase in intracellular Ca2 was lower in
immature DC (Fig. 2, upper panel). These results are indica-
tive of a stage speci¢c regulation of P2X and P2Y receptors
during the di¡erentiation of DC from blood precursor cells.
3.4. DC express mRNA for ATP and AMP metabolizing
enzymes
Signaling through P2 receptors is terminated through the
hydrolysis of extracellular ATP by ecto-ATPases and ecto-
apyrases. Ecto-ATPases hydrolyze ATP to ADP, ecto-apyr-
ases catabolize ADP and ATP to AMP, which is then ca-
tabolized to adenosine by the ecto-5P-nucleotidase. CD73
has been identi¢ed as the major ecto-5P-nucleotidase, whereas
CD39 is an ecto-apyrase. RT-PCR analyses were performed
to investigate whether DC express mRNA for both enzymes.
As shown in Table 2, mRNA for CD39 and CD73 was de-
tectable in DC on day 4 and day 7 independent of further
cytokine stimulation. CD73 mRNA was also found in all
other cell lines tested except for the mouse cell line, CD39
mRNA was not detectable in LB23 and in the mouse cell line.
Fig. 2. Extracellular ATP activates P2Y and P2X receptors. Mono-
cyte derived DC were either cultured with GM-CSF and IL-4 alone
(immature, upper panel) or stimulated for 2 days with the matura-
tion cocktail (IL-1L, IL-6, TNF-K and PGE2) (mature, lower panel).
Cells were loaded with FURA-2 and ATP was added at the indi-
cated concentrations. Changes in £uorescence intensity re£ecting lev-
els of free intracellular Ca2 over the time are shown. Ca2 free me-
dium was obtained by addition of equimolar concentrations of
EGTA. Graph is superimposed by a computer assisted smoothed
line.
Fig. 3. Degradation of extracellular ATP and AMP by DC. DC
were cultured with GM-CSF and IL-4 alone (immature DC, left
panel) or stimulated with the maturation cocktail (IL-1L, IL-6,
TNF-K, PGE2) for 48 hours (right panel). Cells were incubated
with [3H]AMP (upper panel) or [3H]ATP (lower panel). At indicated
timepoints, aliquots were taken and the metabolites [3H]ADP,
[3H]AMP and [3H]adenosine were measured. Amounts of metabo-
lites are shown in cpm.
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3.5. DC degrade extracellular ATP and AMP
For functional analyses, DC were incubated with [3H]ATP
or AMP. At indicated timepoints, aliquots of the cell suspen-
sion were spotted onto thin layer chromatography sheets and
the degradation products [3H]ADP, [3H]AMP and [3H] ad-
enosine were separated and measured as described above.
As shown in Fig. 3, DC show a very high activity of ATPase
independent of their maturation stage (see upper and lower
panels). After 1 min, [3H]ATP was almost undetectable. In-
terestingly, the hydrolysis of ATP did not lead to an increase
in ADP but in AMP and adenosine indicating the presence of
a pyrophosphate hydrolase. When [3H]AMP was added as a
starter nucleotide to investigate the activity of an ecto-5P-nu-
cleotidase, it was rapidly catabolized resulting in an increase
in adenosine. There was no di¡erence in enzyme activity be-
tween mature and immature DC (see upper and lower panel).
4. Discussion
In the present study we demonstrate that human monocyte
derived DC express functional P2 receptors. By RT-PCR we
show for the ¢rst time that DC express mRNA for P2Y and
P2X receptors. This ¢nding is underlined by functional studies
where, in contrast to Liu et al. [23], we could detect not only
metabotropic P2Y receptors but also ionotropic P2X recep-
tors. In contrast to other myeloid cells where there is a clear
stage speci¢c expression of P2Y receptors [25], on human DC
P2Y and P2X receptors were simultaneously expressed inde-
pendent of their maturation stage. In functional analyses,
however, we found increased Ca2 release after the matura-
tion stimulus as well as prolonged Ca2 in£ux through the
plasma membrane. This might indicate quantitative changes
in receptor expression during the maturation of DC. In addi-
tion we found an additive e¡ect of ATP and TNF-K on the
upregulation of the cell surface markers CD80, CD83 and
CD86 during the maturation of DC. As ATP alone shows
only moderate e¡ects it is most likely that ATP acts as a
cofactor for DC maturation.
Extracellular ATP is very rapidly hydrolyzed by DC thus
protecting the cells from ATP induced apoptosis [22] which is
mediated by the P2X7 receptor [29] as well as from uncon-
trolled stimulation. RT-PCR clearly showed the expression of
the ecto-5P-nucleotidase CD73 and the ecto-apyrase CD39.
Again in contrast to other myeloid leukocytes where the ex-
pression is developmentally regulated [25], DC express both
enzymes during all maturation stages. This is supported by
functional analyses where no di¡erences in activity were ob-
served. The expression of these putative ecto-enzymes by DC
at all stages of their di¡erentiation might be important to
protect these crucial cells at their immature antigen processing
stage in the peripheral tissues as well as their mature, T cell
sensitizing stage in the lymphoid organs.
In summary, these ¢ndings underline that ATP receptors
and ATPases play an important role during di¡erentiation
and maturation of DC, which are in£uenced by the nucleotide
concentration and the in£ammatory cytokines.
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DC d4 + +




RNA was extracted from the indicated cells and cell lines. DC were
treated and harvested as in Table 1. RT-PCR was performed with
primers speci¢c for CD39 and CD73.
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